双氢青蒿素哌喹群体给药对赞比亚南部疟疾的短期影响:整群随机对照试验
该整群随机对照试验在赞比亚南部评估2轮社区-wide和家庭-level双氢青蒿素哌喹群体给药(MDA)对比无群体治疗的短期效果。结论认为2轮MDA可快速降低感染患病率、感染发病率和确诊病例发病率,尤其在低传播区。
要点
- 家庭-level焦点MDA对所有终点均未观察到显著影响。
核心结论
- 2轮双氢青蒿素哌喹群体给药快速降低了感染患病率、感染发病率和确诊病例发病率,尤其在低传播区。
研究设计与样本
- 赞比亚南部整群随机对照试验,比较2轮社区-wide与家庭-level双氢青蒿素哌喹MDA及无群体治疗。
- 研究终点包括儿童疟原虫患病率、感染发病率和确诊病例发病率。
- 临床试验注册号NCT02329301。
主要发现
- 所有终点在干预后均显著下降,与治疗分组无关。
- 高传播区未观察到治疗组间差异。
- 家庭-level焦点MDA对所有终点均未观察到显著影响。
临床怎么用
- 在低传播区可考虑采用2轮DHAp社区-wide MDA快速清除疟原虫感染并降低传播。
- 高传播区MDA对感染发病率有降低趋势,但对患病率未见组间差异。
- 家庭-level焦点MDA在本试验中未显示显著效果,不宜作为独立策略推广。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mass drug administration (MDA) using dihydroartemisinin plus piperaquine (DHAp) represents a potential strategy to clear Plasmodium falciparum infections and reduce the human parasite reservoir. METHODS: A cluster-randomized controlled trial in Southern Province, Zambia, was used to assess the short-term impact of 2 rounds of community-wide MDA and household-level (focal) MDA with DHAp compared with no mass treatment. Study end points included parasite prevalence in children, infection incidence, and confirmed malaria case incidence. RESULTS: All end points significantly decreased after intervention, irrespective of treatment group. Parasite prevalence from 7.71% at baseline to 0.54% after MDA in lower-transmission areas, resulting in an 87% reduction compared with control (adjusted odds ratio, 0.13; 95% confidence interval, .02-.92; P = .04). No difference between treatment groups was observed in areas of high transmission. The 5-month cumulative infection incidence was 70% lower (crude incidence rate ratio, 0.30; 95% confidence interval, .06-1.49; P = .14) and 58% lower (0.42; .18-.98; P = .046) after MDA compared with control in lower- and higher-transmission areas, respectively. No significant impact of focal MDA was observed for any end point. CONCLUSIONS: Two rounds of MDA with DHAp rapidly reduced infection prevalence, infection incidence, and confirmed case incidence rates, especially in low-transmission areas. CLINICAL TRIALS REGISTRATION: NCT02329301.
引用
- Eisele TP, Bennett A, Silumbe K, et al. Short-term Impact of Mass Drug Administration With Dihydroartemisinin Plus Piperaquine on Malaria in Southern Province Zambia: A Cluster-Randomized Controlled Trial. J Infect Dis. 2016. PMID: 27923947
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。